ArticleFrontiers in nutrition2026
Creatine supplementation on fatigue related to post-COVID-19 condition-fatigue study: a randomized controlled trial.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-COVID-19 condition (PCC) is characterized by fatigue, dyspnea, and muscle pain, with treatment including physical exercise and nutritional support. Creatine supplementation under these conditions may increase the total body creatine pool, thereby increasing muscular phosphocreatine availability and improving the energy substrate supply to sustain activity and reduce fatigue. This study investigated the efficacy of creatine supplementation in alleviating fatigue symptoms in patients with PCC, as well as its effects on quality of life, lung function, physical performance, body composition, and muscle strength. Methods: This randomized, single-blind, placebo-controlled pilot study assessed supplementation with either 6 g or 18 g of creatine per day or 6 g of maltodextrin (placebo) combined with physical activity three times a week over 4 weeks. Participants with PCC who experienced fatigue [score ≥4 on the revised Piper Fatigue Scale (PFS-R)] underwent physical examination; laboratory evaluation; pulmonary function tests; muscle ultrasound; respiratory and peripheral muscle strength assessments; body composition analysis; physical capacity tests; and questionnaires on quality of life, dyspnea, anxiety, and depression before and after the intervention. Difference-in-differences (DID) between these two time points were compared across the intervention groups and the control arm. Results: Sixty-seven individuals were randomized. Participants were predominantly female (76.6%), with a mean age of 52 ± 12 years, body weight of 82.6 (73.1-93.4) kg, and height of 1.63 ± 0.07 m. A total of 58 completed the protocol: 21 in the 6 g/day group, 19 in the 18 g/day group, and 18 in the placebo arm. When the difference-in-differences (DiD) in the PFS-R before and after the intervention was assessed, a score change of -2.05 was observed in the 6 g/day arm [95% confidence interval (CI): -3.47 to -0.63; Conclusions: Creatine supplementation at 6 g/day was associated with improvements in fatigue and peripheral muscle strength in patients with PCC, with a favorable safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.